Anidulafungin

Tags: Drug.

Anidulafungin or Eraxis (Ecalta in Europe) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005. Pfizer gained approval by the Food and Drug Administration (FDA) on February 21 2006; it was previously known as LY303366. There is preliminary evidence it has a similar safety profile to caspofungin.

thumbnail

ATC prefix

J02

ATC suffix

AX06

CAS number

166663-25-8

DrugBank

DB00362

FDA UNII code

9HLM53094I

IUPAC name

N-[(3S6S9S11R15S18S20R21R24S25S26S)-6-[(1S2R)-12-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11202125-tetrahydroxy-315-bis[(1R)-1-hydroxyethyl]-26-methyl-258141723-hexaoxo-147131622-hexaazatricyclo[22.3.0.0913]heptacosan-18-yl]- 4-4-[4-(pentyloxy)phenyl]phenylbenzamide

PubChem

166548